Marksans Pharma Ltd — Q1 FY27 earnings call
Summary generated by AI from the official transcript Marksans Pharma Ltd filed with BSE on 20 Aug 2026. Every statement cites a verbatim quote from that document — open any citation to read it. This is a record of what management said, not a recommendation. How we check these summaries
The short read
Marksans Pharma reported Q1 FY27 revenue of INR841 crores, up 35.6% year-on-year, with EBITDA of INR213 crores and PAT of INR159 crores, both described as the highest ever quarterly figures. UK and Europe revenue grew 74.7% year-on-year to INR356 crores, aided by the QliniQ acquisition, while North America grew 15.1% and Australia and New Zealand grew 53.7%. Management discussed the QliniQ and ABCnow acquisitions, gross margin drivers, working capital improvement, and plans for further expansion in Europe.
Numbers mentioned
Revenue: INR841 crores (Q1 FY27)
p. 3
“We delivered INR841 crores of revenue, up 35.6% year-on-year, with our highest-ever quarterly EBITDA of INR213 crores and highest ever quarterly PAT of INR159 crores, alongside our cash balance crossing INR1,000 crores for the first time.”
Mark Saldanha, page 3 of the filed PDF · View the filing
UK and Europe revenue: INR356 crores (Q1 FY27)
p. 3
“UK and Europe delivered the highest ever quarterly revenue of INR356 crores, growing 74.7% year-on-year.”
Mark Saldanha, page 3 of the filed PDF · View the filing
North America revenue: INR377 crores (Q1 FY27)
p. 3
“in North America, we delivered INR377 crores of revenue, growing 15.1% year-on-year.”
Mark Saldanha, page 3 of the filed PDF · View the filing
Australia and New Zealand revenue: INR88 crores (Q1 FY27)
p. 4
“In Australia and New Zealand, we delivered INR88 crores of revenue, up 53.7% year-on-year.”
Mark Saldanha, page 4 of the filed PDF · View the filing
Operating revenue: INR840.8 crores (Q1 FY27)
p. 4
“Operating revenue for Q1 FY27 stood at INR840.8 crores, up 35.6% year-on-year from INR620 crores in Q1 of FY26.”
Jitendra Sharma, page 4 of the filed PDF · View the filing
Gross profit: INR497.3 crores (Q1 FY27)
p. 4
“Gross profit stood at INR497.3 crores, up 38.9% year-on-year from INR358.2 crores.”
Jitendra Sharma, page 4 of the filed PDF · View the filing
Gross margin: 59.1% (Q1 FY27)
p. 4
“gross margin improved to 59.1% from 57.8%, an expansion of 138 basis points.”
Jitendra Sharma, page 4 of the filed PDF · View the filing
EBITDA: INR213 crores (Q1 FY27)
p. 4
“EBITDA stood at INR213 crores, compared with INR100.1 crores in Q1 FY26, representing 112.8% year-on-year growth.”
Jitendra Sharma, page 4 of the filed PDF · View the filing
EBITDA margin: 25.3% (Q1 FY27)
p. 4
“EBITDA margin expanded to 25.3% from 16.1%, an improvement”
Jitendra Sharma, page 4 of the filed PDF · View the filing
Profit after tax: INR159.4 crores (Q1 FY27)
p. 5
“Profit after-tax stood at INR159.4 crores compared with INR58.2 crores in Q1 FY26, representing a 173.9% year-on-year increase.”
Jitendra Sharma, page 5 of the filed PDF · View the filing
PAT margin: 18.4% (Q1 FY27)
p. 5
“PAT margin improved to 18.4% from 9.3% sequentially, PAT increased from INR149 crores in Q4 FY2026 with PAT margin improving from 16.7% to 18.4%.”
Jitendra Sharma, page 5 of the filed PDF · View the filing
Cash from operations: INR185 crores (Q1 FY27)
p. 5
“We generated INR185 crores of cash from operations during the quarter.”
Jitendra Sharma, page 5 of the filed PDF · View the filing
Free cash flow: INR152 crores (Q1 FY27)
p. 5
“After net capex of INR33 crores, free cash flow stood at INR152 crores.”
Jitendra Sharma, page 5 of the filed PDF · View the filing
Working capital cycle: approximately 132 days (Q1 FY27)
p. 5
“Our working capital cycle improved to approximately 132 days compared with approximately 159 days in Q1 FY2026 and 138 days forFY2026 as a whole”
Jitendra Sharma, page 5 of the filed PDF · View the filing
R&D spend: INR23.2 crores (Q1 FY27)
p. 5
“R&D spend for the quarter was INR23.2 crores or 2.8% of consolidated revenue compared with INR12.1 crores and 2% in Q1 of FY2026.”
Jitendra Sharma, page 5 of the filed PDF · View the filing
Cash balance: INR1,058 crores (Q1 FY27)
p. 5
“We ended the quarter with a cash balance of INR1,058 crores compared with INR711 crores at the end of Q1 FY2026.”
Jitendra Sharma, page 5 of the filed PDF · View the filing
QliniQ contribution to revenue: approximately INR44 crores (Q1 FY27)
p. 3
“During the quarter, we completed the acquisition of QliniQ B.V in Netherlands, which contributed approximately INR44 crores of revenue in Q1.”
Mark Saldanha, page 3 of the filed PDF · View the filing
What management said it would do
A record of statements made on the call, in the words management used. Parakho does not forecast, endorse or assess them, and their presence here is not a view on whether they will happen.
Revenue — INR4,000 crores · within the next two years
stated firmly by Mark Saldanha
p. 6
“we are still very much on our target of hitting INR4,000 crores within the next two years. So I think we still stand by it.”
Mark Saldanha, page 6 of the filed PDF · View the filing
Revenue growth — 15% to 20% · FY27
stated conditionally by Mark Saldanha
p. 7
“No, I think we'll stick with that plan because of the volatility that you see, the geopolitical scenarios that you see prevailing, surrounding us and pretty much all countries.”
Mark Saldanha, page 7 of the filed PDF · View the filing
Gross margin — 55% to 56%
stated conditionally by Mark Saldanha
p. 6
“in terms of sustainability of that 25-odd percent -- yes, 59%, I think we should be around 55%, 56% gross margin per se.”
Mark Saldanha, page 6 of the filed PDF · View the filing
EBITDA margin — 21% to 22% · end of FY27
stated firmly by Mark Saldanha
p. 12
“Yes. End of the year, 21% to 22% is achievable. Yes.”
Mark Saldanha, page 12 of the filed PDF · View the filing
QliniQ revenue — INR150 crores to INR175 crores · FY27
stated conditionally by Jitendra Sharma
p. 5
“We expect QliniQ will do around INR150 crores to INR175 crores in terms of the revenue overall for the year.”
Jitendra Sharma, page 5 of the filed PDF · View the filing
Europe revenue — INR180 crores · FY27
stated conditionally by Mark Saldanha
p. 5
“We expect to end this year by around about -- between EUR14 million to EUR15 million, that's really about 40% above.”
Mark Saldanha, page 5 of the filed PDF · View the filing
Europe revenue — INR1,000-odd crores · within five years
stated as an aspiration by Mark Saldanha
p. 12
“In the next three to five years, let's say, more or less within five years, we are hoping that that geography can do about INR1,000-odd crores.”
Mark Saldanha, page 12 of the filed PDF · View the filing
Germany entity revenue — early third quarter
stated conditionally by Mark Saldanha
p. 7
“So Germany, we expect some revenue to be generated soon, maybe early third quarter.”
Mark Saldanha, page 7 of the filed PDF · View the filing
Ireland entity revenue — next financial year
stated conditionally by Mark Saldanha
p. 7
“we are hopeful for next year to see some revenue in the next financial year, not this year.”
Mark Saldanha, page 7 of the filed PDF · View the filing
India manufacturing capacity — probably another unit in India · one to two years
stated as an aspiration by Mark Saldanha
p. 13
“I think we have a year to two years to work towards achieving this objective.”
Mark Saldanha, page 13 of the filed PDF · View the filing
US revenue — $300 million · immediate objective
stated firmly by Mark Saldanha
p. 14
“But I think our immediate objective is to first reach our next benchmark of $300 million in the U.S.”
Mark Saldanha, page 14 of the filed PDF · View the filing
US revenue — $400 million · maybe five years
stated as an aspiration by Mark Saldanha
p. 14
“we are now working towards a $300 million and then we'll probably look at a $400 million, if you have to look at a horizon of maybe five years.”
Mark Saldanha, page 14 of the filed PDF · View the filing
Product portfolio — double portfolio · next two to three years
stated as an aspiration by Mark Saldanha
p. 14
“we have taken this objective in the next two to three years to literally double our portfolio in every country that we are in.”
Mark Saldanha, page 14 of the filed PDF · View the filing
Consolidated revenue — doubling revenue · next five years
stated as an aspiration by Mark Saldanha
p. 16
“when we did INR3,000 crores we are now giving a visibility of doubling our revenue within, the next five years.”
Mark Saldanha, page 16 of the filed PDF · View the filing
Goa unit 2 (Teva facility) revenue — INR80 crores
stated as an aspiration by Mark Saldanha
p. 13
“We had projected about moving towards an INR80 crores revenue generation from that plant. We are right now at INR50-plus crores.”
Mark Saldanha, page 13 of the filed PDF · View the filing
Q&A highlights
Management's answers to analyst questions, in Parakho's words rather than a transcript. Each row names who answered and carries the verbatim quote it was drawn from.
Effective date was 1 April 2026, consolidated from Q1; QliniQ expected to contribute INR150-175 crores for the year.
Answered by Jitendra Sharma
Asked by Ahmed Madha: How is QliniQ revenue accounted for and what is the outlook for the acquisitions and organic Europe efforts for FY27?
p. 5
“the effective date for the transaction was 1st of April 2026. So we have consolidated the first quarter numbers in our June quarter consolidated financials.”
Jitendra Sharma, page 5 of the filed PDF · View the filing
Management said current margins are boosted by low-cost inventory and expect margins to normalize to 55-56%.
Answered by Mark Saldanha
Asked by Ahmed Madha: How should gross margin sustainability be viewed given high-cost inventory replacement?
p. 6
“we do believe that as and when this war does end, there will be -- it will go back to its normal levels relatively very fast.”
Mark Saldanha, page 6 of the filed PDF · View the filing
Order book remains strong and growth is expected to come from all geographies, not just the US.
Answered by Mark Saldanha
Asked by Ahmed Madha: How does the US order book look for the rest of the season?
p. 6
“the order book is still strong. So that's not a problem. But we do see contribution in this financial year coming from around the geographies.”
Mark Saldanha, page 6 of the filed PDF · View the filing
Management said it will stick to the existing guidance due to geopolitical volatility.
Answered by Mark Saldanha
Asked by Meet Bhuva: With Q1 bottom-line growth around 25%, will FY27 guidance of 15-20% revenue growth and 20-21% EBITDA margin be revised upward?
p. 7
“No, I think we'll stick with that plan because of the volatility that you see, the geopolitical scenarios that you see prevailing, surrounding us and pretty much all countries.”
Mark Saldanha, page 7 of the filed PDF · View the filing
Management confirmed Q2 revenue should be better than Q1, with Q3 likely the strongest.
Answered by Mark Saldanha
Asked by Deepesh Sancheti: Will Q2 and Q3 be stronger than Q1 as in prior years?
p. 9
“revenue, definitely, the Q2 will be better than the Q1 and Q3 will be probably the strongest.”
Mark Saldanha, page 9 of the filed PDF · View the filing
Management said ramping up US production is a possibility but they will wait and watch given political uncertainty.
Answered by Mark Saldanha
Asked by Deepesh Sancheti: Is the US strategy to ramp up production domestically given tariff threats?
p. 9
“that possibility of ramping up is always there with us. And we always keep that as an option.”
Mark Saldanha, page 9 of the filed PDF · View the filing
Management said they avoid such risk and prefer to use cash for inorganic growth strategies.
Answered by Mark Saldanha
Asked by Abhi Jain: Should the company use idle cash reserves more efficiently, e.g. via index investing, given the yield gap versus operating ROC?
p. 11
“No, we don't take that factoring or risk. We are not into that. We make sure it is safe.”
Mark Saldanha, page 11 of the filed PDF · View the filing
UK growth is entirely organic; excluding QliniQ, UK grew over 50% year-on-year.
Answered by Jitendra Sharma
Asked by Anand Moore: How much of UK and Europe growth is organic versus from the QliniQ acquisition?
p. 12
“Excluding the QliniQ number, in our U.K. business, we have achieved growth of over 50% on a year-on-year basis during the quarter. That is all organic.”
Jitendra Sharma, page 12 of the filed PDF · View the filing
Management said they are exploring targets but nothing concrete yet, and may need another India unit.
Answered by Mark Saldanha
Asked by Aejas Lakhani: Is the company planning additional manufacturing capacity given constraints?
p. 13
“We are looking at a couple of targets. It is too early to mention whether it will go as per plan.”
Mark Saldanha, page 13 of the filed PDF · View the filing
UK is split roughly evenly between Rx and OTC, while Europe will be more Rx-weighted.
Answered by Mark Saldanha
Asked by Nitin Agarwal: What is the OTC/Rx mix expected in Europe versus the UK?
p. 14
“in Europe, it's going to be tilting more towards Rx, maybe 80% or 85% Rx and 15% OTC.”
Mark Saldanha, page 14 of the filed PDF · View the filing
Management pointed to the existing goal of doubling revenue within five years as already ambitious.
Answered by Mark Saldanha
Asked by Jugal Shah: Given cash reserves and scale, shouldn't guidance be more aspirational than 15-20% growth?
p. 16
“we spoke about doubling our revenue. So that itself is, I mean, how many companies do you know that talk about doubling their revenue?”
Mark Saldanha, page 16 of the filed PDF · View the filing
Risks flagged
Geopolitical war-related disruption raising freight and raw material costs
p. 6
“there are obviously other parameters within the war -- due to the war, which is having an impact like freight or some higher cost of raw material coming in”
Mark Saldanha, page 6 of the filed PDF · View the filing
Rest of World markets struggling due to war-related transportation disruption
p. 7
“the other markets besides the western markets are struggling a bit because of the war scenarios, because of vessels unable to pass and the transportation becoming one of the biggest hurdles in those regions.”
Mark Saldanha, page 7 of the filed PDF · View the filing
Uncertainty around potential US tariffs/duties
p. 9
“I would not put much weightage on what he says because it may change pretty much within two days or three days or whenever.”
Mark Saldanha, page 9 of the filed PDF · View the filing
Unpredictability of M&A timelines
p. 9
“M&A is unpredictable and timelines are not fixed.”
Mark Saldanha, page 9 of the filed PDF · View the filing
Consumer affordability pressure in the US due to fuel prices
p. 14
“We see the fuel prices going up. Consumers struggle to fill -- affordability on filling their gas tanks.”
Mark Saldanha, page 14 of the filed PDF · View the filing
Uncertainty on timing of next USFDA inspection
p. 8
“There is no definite time lines as in such because they can come any moment, although one of our plants was recently audited less than 12 months back.”
Mark Saldanha, page 8 of the filed PDF · View the filing
Generated by claude-sonnet-5. Source: the transcript as filed with BSE. We link to the exchange's copy; we do not host transcripts. Parakho is a data and screening tool, not an investment adviser — nothing here is a recommendation to buy, sell or hold.